Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder CancerIan M. McElree, Vignesh T. Packiam, Ryan L. Steinberg et al.|JAMA Network Open|2023Cited by 116
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder CancerIan M. McElree, Vignesh T. Packiam, Ryan L. Steinberg et al.|The Journal of Urology|2022Cited by 71
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancerPhani T. Chevuru, Vignesh T. Packiam, Ian M. McElree et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 59
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder CancerWei Shen Tan, Vignesh T. Packiam, Ian M. McElree et al.|European Urology Oncology|2023Cited by 38
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancerJacob Taylor, Yair Lotan, Ashish M. Kamat et al.|British Journal of Urology|2024Cited by 27